Amgen has appointed David W. Gibbs, former CEO of Yum! Brands, to its Board of Directors. Gibbs brings extensive leadership experience from the consumer brand sector and will serve on Amgen's Audit and Compensation Committees. His background in digital transformation and global expansion is expected to support Amgen's efforts in launching innovative treatments and expanding patient reach. This move strengthens Amgen's board with 13 directors, 12 of whom are independent.
Amgen's stock is trading at USD 444.00 on Pluang as of Oct 27, 2026 05:01 WIB, showing a 1.08% increase in the last day. The company has a market cap of $237.48 billion, reflecting its significant presence in the health sector. Investors holding Amgen typically keep their positions for about 73 days on the platform.
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi immunotherapy reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer, extending median survival to 21.1 months from 12.7 months with Imf...
Amgen announced Phase 3 DeLLphi-305 trial results where IMDELLTRA combined with AstraZeneca's IMFINZI reduced death risk by 58% and extended median overall survival to 21.1 months in extensive-stage small cell lung cancer patients. Nearly 80% of pati...
